NCT02755324已完成不适用
Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding
Leiden University2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年10月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.
研究概览
简要总结
Groups of 3 or 7 volunteers will be exposed to a predetermined number of male Schistosoma mansoni cercariae until 10 volunteers are found infected.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is aged ≥ 18 and ≤ 45 years and in good health.
- •Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- •Subject is able to communicate well with the investigator, is available to attend all study visits.
- •Subject will remain within Europe (excluding Corsica) during the study period and is reachable by mobile telephone from week 3 to week 12 of the study period.
- •Subject agrees to refrain from blood donation throughout the study period.
- •For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
- •Subject has signed informed consent.
排除标准
- •Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
- •body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;
- •positive HIV, hepatitis B or hepatitis C screening tests;
- •the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period;
- •history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
- •any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
- •history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
- •Any clinically significant abnormalities (including extended QT interval) on electrocardiogram
- •The chronic use of any drug known to interact with praziquantel, or artesunate or lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study.
- •For female subjects: positive urine pregnancy test at screening.
- •Any history of schistosomiasis or treatment for schistosomiasis.
- •Positive serology for schistosomiasis or elevated serum or urine circulating anodic antigen or positive Schistosoma serology at baseline.
- •Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel or, artesunate or lumefantrine.
- •Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.
结局指标
主要结局
Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.
时间窗: 20 weeks
The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA).
时间窗: 12 weeks
次要结局
- Average number of weeks until positive serum circulating anodic antigen test(12 weeks)
- Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals(1 year)
- Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals(1 year)
- Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group(12 weeks)
研究者
Meta Roestenberg
MD, PhD
Leiden University Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Single-sex Female Controlled Human Schistosomiasis Mansoni InfectionSchistosomiasisSchistosomiasis MansoniNCT04269915Leiden University Medical Center13
进行中（未招募）
不适用
A study to investigate the dose of Bilharzia worms that can be safely used to infect humans as a first step to enable testing Bilharzia vaccinesInfections and InfestationsSchistosomiasis [bilharziasis]SchistosomiasisISRCTN14033813ondon School of Hygiene & Tropical Medicine66
已完成
不适用
Establishing a Single-sex Controlled Human Schistosoma mansoni Infection Model: safety and dose finding10019381SchistosomiasisbilharziaNL-OMON46890eids Universitair Medisch Centrum17
已完成
不适用
Repeated Controlled Human Schistosoma Mansoni InfectionSchistosoma MansoniSchistosomiasisNCT05085470Leiden University Medical Center24
已完成
不适用
Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical CenterNecator Americanus InfectionNCT03126552Leiden University Medical Center4